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See Article, pages 306–311Small hepatocellular carcinoma (HCC) is usually detected in the
setting of screening in cirrhotic patients. Although the role of
screening continues to be challenged [1], it is now reasonably
well accepted, and screening is now part of clinical practice [2].
Indeed, it seems now impossible to do a randomized control trial
to test this. We attempted this, but with proper informed con-
sent, we found that patients do not accept randomization into a
non-screened arm [3]. The aim of screening is, of course, to detect
small HCC that can be treated by local resection/ablation or liver
transplantation. It is generally accepted that these therapies pro-
vide the best chance of long-term survival, although recurrence
and emergence of new HCCs may impact on tumor free survival
[4–6].
However, it is well known that small HCCs can remain
untreated and dormant for signiﬁcant periods of time [7,8]. Well
differentiated HCCs with increased echogenicity on ultrasound
have been described as having doubling times of >300 days [7],
although small HCCs tended to have low echogenicity in a report
from Japan where a number of HCCs between 1 and 2 cm in
diameter did not change size over a 10–20 month period [8].
Thus questions have always existed – how small is small?
How small can you go with just observation without interven-
tion? The manuscript by Midorikawa et al., attempts to answer
these questions with interesting results and challenging conclu-
sions [9].
EASL and AASLD guidelines deﬁne the smallest HCC as simply
very early stage HCC (<2 cm) [4,5]. It is recommended that lesions
<1 cm should be observed. If the lesion is between 1–2 cm with-
out the characteristic ﬁndings of arterial hyper vascularity and
venous or delayed phase washout on 4 phase CT scan or contrast
enhanced MRI, then biopsy is recommended. APASL guidelines do
not recommend biopsy but recommend a series of additional
imaging techniques aimed at detection of Kupffer cell uptake
[6,10]. Once HCC is diagnosed, all 3 guidelines recommend local
therapies (ablation, resection or transplantation).
Japanese investigators have studied small or early HCC for
some time [9,11,12]. There is also a recent international consen-
sus report on the pathology of such lesions [13]. MidorikawaJournal of Hepatology 20
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in situ. These lesions were non-enhancing on arterial phase imag-
ing but hypovascular on the portal phase. Such lesions were
1.3 cm in diameter on average. Biopsy features included well-
differentiated HCC, hyper cellularity and the presence of portal
tracts (Gilson’s triad). The abnormal cells showed stromal inva-
sion into the intra-tumoral portal tracts and structural atypia
(Supplementary Fig. 1 in [9]). Such lesions are currently recog-
nized in AASLD, EASL and Japanese guidelines [4,5,14].
In the study published in this issue of the Journal, only some
patients were treated (n = 12) whilst 46 underwent resection.
Follow-up was compared to 201 patients with ‘‘overt’’ HCC
(<2 cm lesion with characteristic imaging ﬁndings) that under-
went resection. Sixteen patients with overt HCC were observed.
The authors attempted to establish the difference between the
beneﬁt of resection over observation of ‘‘early’’ HCC and the ben-
eﬁt of resection over observation in patients with overt HCC. This
analysis showed that the survival difference was only 1.3 months
(74.7 months vs. 73.4 months). Consequently the authors con-
cluded that ‘‘early’’ HCC under their deﬁnition does not require
treatment. Patients can be observed and monitored: when overt
HCC is diagnosed then local treatment would be indicated.
What are we to make of all this? There are several issues with
this paper. Firstly, it is not exactly clear why early HCC patients
were not treated (choice and co-morbidities) and it is also not
clear what they died of (although advanced HCC it is implied as
the cause). Secondly, there is emerging data that the use of
immunohistochemical markers (such as glypican-3, glutamine
synthetase, and heat shock proteins 70) can be used to deﬁne true
HCC. A combination of these markers may have a sensitivity of up
to 40% and a speciﬁcity of 100%, although a recent analysis of
biopsy material found little advantage compared to expert
pathology review [15]. The use of these markers is mentioned
by the international pathology consensus group [13]. Unfortu-
nately the usefulness of these markers in early but not overt
HCC was not investigated in the Midorikawa et al., study. Thirdly,
the pathological analysis is mostly based on resected specimens.
Fine needle aspiration biopsy (FNAB) was used in the non-treated
patients but the ﬁndings between the FNAB specimens and the
resected specimens were not analyzed nor discussed. Lastly,
although all early HCC patients had well differentiated lesions
2/46 (4%) had vascular invasion – hardly early HCC/carcinoma
in situ.13 vol. 58 j 210–211
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Fig. 1. Algorithm proposed by Midorikawa et al. [9]. (⁄) Lesion <1 cm may be
observed and not biopsied. () Pathological deﬁnition of early HCC deﬁned in
[9,12,13].
JOURNAL OF HEPATOLOGYAdditional concerns include the lack of data on patients with
radiological ﬁndings of no arterial enhancement but a portal
phase defect in which the biopsy could not diagnose HCC at all.
The authors have not reported on this group of patients. Presum-
ably such patients exist and had dysplastic nodules. It also
appears that in this group no patients actually had histological
ﬁndings of HCC not ﬁtting the pathological deﬁnition of early
HCC. Both these issues are very important in judging the clinical
usefulness and utility of biopsy combined with a watch and wait
approach.
Although the ﬁndings in this paper have signiﬁcant caveats,
they do remind us that HCC at its early or very early stages (car-
cinoma in situ) can growth very slowly. The concept that it can be
observed until progression occurs seems provocative. It would
seem that it is not unreasonable to undertake ‘‘safe’’ treatments
(e.g., ablation) for such lesions, but more ‘‘invasive’’ therapies
such as resection or liver transplantation appear to be best
reserved for overt HCC. Such approaches are not currently stan-
dard of practice according to EASL, AASLD and APASL guidelines,
but the lesions reported in the paper are in fact recognized in
these guidelines. The data in this paper needs consideration
and discussion when the guidelines are next revised. Personally,Journal of Hepatology 201I think that the clinical usefulness and utility of the approach sug-
gested by Midorikawa et al., (Fig. 1) will be limited, but discussion
of this issue needs to take place.Conﬂict of interest
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